0001144204-13-019384.txt : 20130402 0001144204-13-019384.hdr.sgml : 20130402 20130401181600 ACCESSION NUMBER: 0001144204-13-019384 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20121231 FILED AS OF DATE: 20130402 DATE AS OF CHANGE: 20130401 EFFECTIVENESS DATE: 20130402 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Synthetic Biologics, Inc. CENTRAL INDEX KEY: 0000894158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133808303 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12584 FILM NUMBER: 13732749 BUSINESS ADDRESS: STREET 1: 155 GIBBS STREET STREET 2: SUITE 412 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: (734) 332-7800 MAIL ADDRESS: STREET 1: 155 GIBBS STREET STREET 2: SUITE 412 CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: ADEONA PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: PIPEX PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20061214 FORMER COMPANY: FORMER CONFORMED NAME: SHEFFIELD PHARMACEUTICALS INC DATE OF NAME CHANGE: 19970730 NT 10-K 1 v340142_nt10-k.htm NT 10-K

 

 

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 12B-25

 

COMMISSION FILE NUMBER: 001-12584

 

 

 

NOTIFICATION OF LATE FILING

 

 

Check One:

 

[X] Form 10-K and Form 10

[  ] Form 20-F

[  ] Form 11-K

[  ] Form 10-Q and Form 10

[  ] Form 10-D

[  ] Form N-SAR

[  ] Form N-CSR

 

For Period Ended: December 31, 2012

 

[  ]  Transition Report on Form 10-K

[  ]  Transition Report on Form 20-F

[  ]  Transition Report on Form 11-K

[  ]  Transition Report on Form 10-Q

[  ]  Transition Report on Form N-SAR

 

For the Transition Period Ended: N/A

 

 

 

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:  N/A


 
 


 

 

PART I. REGISTRANT INFORMATION.

 

The Registrant is Synthetic Biologics, Inc. (the "Company"). The address of the Company’s principal executive office is 155 Gibbs Street, Suite 412, Rockville, Maryland 20850.

 

PART II. RULES 12B-25 (b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check appropriate box.)

 

[X](a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

 

[X](b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

 

[  ] (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III. NARRATIVE

 

 The Registrant is unable to file, without unreasonable effort and expense, its Annual Report on Form 10-K for the period ended December 31, 2012 because the Registrant is still compiling information and the auditors have not completed their review of the financial statements for that period. It is anticipated that the Annual Report on Form 10-K, along with the audited financial statements, will be filed on or before the deadline.

 

PART IV. OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification:

 

C. Evan Ballantyne                (734) 332-7800

 

(2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).    [X]  Yes      [  ]  No

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings to be included in the subject report or portion thereof?     [X] Yes      [  ] No

2
 

 

The Registrant does not anticipate having any revenue for year ended December 31, 2012. General and administrative expenses are expected to be $5.0 million for the year ended December 31, 2012, compared to $2.6 million for the same period in 2011. Research and development expenses are expected to be $12.3 million for the year ended December 31, 2012, compared to $3.3 million for the same period in 2011. Net loss is expected to be $17.1 million for the year ended December 31, 2012 compared to $8.1 million for the same period in 2011.

 

3
 

 

 

SYNTHETIC BIOLOGICS, INC.

 

 

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

 

   
   
Dated: April 1, 2013 By:  /s/ C. Evan Ballantyne
  Name: C. Evan Ballantyne
  Title: Chief Financial Officer

 

 

4